Clinical mesenchymal stem cell cryopreservation solution and preparation method thereof

A cryopreservation solution and mesenchymal stem cell technology, which is applied in the field of clinical mesenchymal stem cell cryopreservation solution and its preparation, can solve the problems of low cell activity and inability to be directly applied, achieve stable cell structure, realize long-distance treatment, reduce Effect of exogenous infection risk

Inactive Publication Date: 2019-02-15
CHENGDU QINGKE BIOTECH
View PDF6 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Aiming at the above-mentioned deficiencies in the prior art, the present invention provides a cryopreservation solution for clinical use of mesenchymal stem cells and a preparation method thereof, whic...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Clinical mesenchymal stem cell cryopreservation solution and preparation method thereof
  • Clinical mesenchymal stem cell cryopreservation solution and preparation method thereof
  • Clinical mesenchymal stem cell cryopreservation solution and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] A cryopreservation solution of mesenchymal stem cells for clinical use, comprising the following components by weight percentage:

[0039] Autologous plasma lysate mixture 5%, human serum albumin 1%, VC injection 0.5%, 10% low molecular weight dextran glucose injection 5%, compound electrolyte injection 24%, glucose sodium chloride injection 28%, compound Amino acid injection 27%, dimethyl sulfoxide 5% and trehalose 4.5%.

[0040] Wherein, the preparation method of autologous plasma lysate mixture is:

[0041] (1) Collect 16 mL of peripheral blood from the donor in EDTA anticoagulant blood collection tubes, and complete the plasma preparation within 2 hours of collection;

[0042] (2) Centrifuge at 4000r / min for 8min, absorb the upper layer of plasma and gently blow the buffy coat to mix the buffy coat and plasma evenly, transfer the plasma and buffy coat to cryopreservation tubes, and temporarily store them in a -80° ultra-low temperature refrigerator stay overnigh...

Embodiment 2

[0049] A cryopreservation solution of mesenchymal stem cells for clinical use, comprising the following components by weight percentage:

[0050] Autologous plasma lysate mixture 1%, human serum albumin 2%, 10% low molecular weight dextran glucose injection 10%, compound electrolyte injection 30%, glucose sodium chloride injection 20%, compound amino acid injection 30%, Dimethyl sulfoxide 2% and trehalose 5%.

[0051] Wherein, the preparation method of autologous plasma lysate mixture is:

[0052] (1) Collect 16 mL of peripheral blood from the donor in EDTA anticoagulant blood collection tubes, and complete the plasma preparation within 2 hours of collection;

[0053] (2) Centrifuge at 4000r / min for 8min, absorb the upper layer of plasma and gently blow the buffy coat to mix the buffy coat and plasma evenly, transfer the plasma and buffy coat to cryopreservation tubes, and temporarily store them in a -80° ultra-low temperature refrigerator stay overnight;

[0054] (3) Res...

Embodiment 3

[0060] A cryopreservation solution of mesenchymal stem cells for clinical use, comprising the following components by weight percentage:

[0061] Autologous plasma lysate mixture 5%, human serum albumin 2%, VC injection 1%, glucose injection 5%, compound electrolyte injection 23.5%, glucose salt injection 25%, compound amino acid injection 30%, two Methyl sulfoxide 4% and trehalose 4.5%.

[0062] Wherein, the preparation method of autologous plasma lysate mixture is:

[0063] (1) Collect 16 mL of peripheral blood from the donor in EDTA anticoagulant blood collection tubes, and complete the plasma preparation within 2 hours of collection;

[0064] (2) Centrifuge at 4000r / min for 8min, absorb the upper layer of plasma and gently blow the buffy coat to mix the buffy coat and plasma evenly, transfer the plasma and buffy coat to cryopreservation tubes, and temporarily store them in a -80° ultra-low temperature refrigerator stay overnight;

[0065] (3) Resuscitate the plasma pr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Concentrationaaaaaaaaaa
Login to view more

Abstract

The invention discloses clinical mesenchymal stem cell cryopreservation solution and a preparation method thereof. The preservation solution comprises the following components in percentage by weight:1-5% of autologous plasma lysate mixed liquor, 1-2% of human serum albumin, 0-1% of VC injection, 5-10% of glucose injection, 20-30% of electrolyte-like solution, 20-30% of glucosamine injection, 20-30% of compound amino acid injection, 2-5% of dimethyl sulfoxide and 2.5-5% of trehalose. The prepared cryopreservation solution can be used for deep low-temperature and long-term storage of cells, and can realize long-distance transportation, so that the distribution range of cells is expanded, the long-distance treatment of stem cells is realized, and the cells can be directly returned after recovery so as to reduce the potential safety hazards caused by complicated operations.

Description

technical field [0001] The invention belongs to the technical field of cell preservation, and in particular relates to a cryopreservation solution for clinical use of mesenchymal stem cells and a preparation method thereof. Background technique [0002] Cell therapy involves the process of cell preparation, expansion, reinfusion, etc. Usually, the place and time of these processes are not consistent, so the cells need to be transported to the destination, and the quality control in the process of cell transport is weak. In the normal temperature environment of the cell, various enzymes in the cell react with other biological macromolecules, the metabolism is vigorous, the aerobic is high, and the energy consumption is large. These physiological processes will produce a large number of oxygen free radicals and lipid peroxides. If they are not removed in time, they will cause changes in environmental pH and osmotic pressure, resulting in cell swelling and death. Due to the inc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A01N1/02
CPCA01N1/0221A01N1/0226
Inventor 高雪华海泉陈静娴赵峻
Owner CHENGDU QINGKE BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap